Shares of Obseva SA (NASDAQ:OBSV) have earned a consensus rating of “Buy” from the eight research firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $32.00.
A number of research analysts recently issued reports on OBSV shares. Zacks Investment Research downgraded Obseva from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. HC Wainwright set a $44.00 price objective on Obseva and gave the stock a “buy” rating in a report on Thursday, March 7th. ValuEngine upgraded Obseva from a “hold” rating to a “buy” rating in a report on Friday, April 26th. Finally, Wedbush set a $38.00 price objective on Obseva and gave the stock a “buy” rating in a report on Friday, May 10th.
NASDAQ OBSV opened at $11.55 on Wednesday. The firm has a market capitalization of $502.24 million, a price-to-earnings ratio of -6.05 and a beta of 1.21. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.73 and a current ratio of 6.73. The stock’s 50-day simple moving average is $12.06. Obseva has a one year low of $9.73 and a one year high of $19.40.
Several large investors have recently bought and sold shares of OBSV. Fosun International Ltd bought a new position in Obseva in the first quarter valued at approximately $2,494,000. Dimensional Fund Advisors LP grew its stake in Obseva by 274.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 70,573 shares of the company’s stock valued at $893,000 after purchasing an additional 51,733 shares in the last quarter. Polar Capital LLP grew its stake in Obseva by 16.7% in the fourth quarter. Polar Capital LLP now owns 175,000 shares of the company’s stock valued at $2,216,000 after purchasing an additional 25,000 shares in the last quarter. Wedbush Securities Inc. grew its stake in Obseva by 86.1% in the first quarter. Wedbush Securities Inc. now owns 38,790 shares of the company’s stock valued at $496,000 after purchasing an additional 17,950 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in Obseva in the fourth quarter valued at approximately $218,000. Institutional investors and hedge funds own 63.58% of the company’s stock.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Recommended Story: How interest rates affect municipal bond prices
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.